Valuation: Oxford Biomedica plc

Capitalization 775M 1.05B 890M 819M 1.44B 97.21B 1.46B 9.59B 3.76B 47.12B 3.94B 3.86B 166B P/E ratio 2026 *
-81.7x
P/E ratio 2027 * 43.5x
Enterprise value 801M 1.09B 920M 847M 1.49B 101B 1.51B 9.92B 3.89B 48.73B 4.08B 3.99B 172B EV / Sales 2026 *
3.49x
EV / Sales 2027 * 2.67x
Free-Float
76.07%
Yield 2026 *
-
Yield 2027 * -
1 day+3.39%
1 week+13.25%
Current month+17.61%
1 month-0.47%
3 months-28.70%
6 months+9.01%
Current year+3.89%
1 week 553
Extreme 553
648
1 month 530
Extreme 530
648
Current year 530
Extreme 530
962
1 year 270
Extreme 270.0035
962
3 years 164.29
Extreme 164.288
962
5 years 164.29
Extreme 164.288
1,678
10 years 148.88
Extreme 148.885
1,678
Manager TitleAgeSince
Chief Executive Officer 64 2023-03-26
Director of Finance/CFO 47 2024-09-01
Chief Operating Officer - 2023-09-30
Director TitleAgeSince
Director/Board Member 60 2018-03-14
Chairman 70 2020-06-23
Director/Board Member 75 2021-02-28
Change 5d. change 1-year change 3-years change Capi.($)
+3.39%+13.25%+114.38%+47.53% 1.05B
+1.01%+5.25%+36.93%+110.19% 52.7B
-5.93%-6.53%+88.06%+22.98% 44.07B
+1.18%-6.67%+98.87%+719.51% 31.19B
+0.78%+7.77%+4.21%-16.45% 26.03B
+2.99%+27.86%+2.19%+1,491.77% 19.5B
-3.93%-0.50%+74.24%-34.28% 18.88B
+1.34%+9.26%+82.04%+242.02% 17.76B
+0.78%+0.78%+39.68%-36.14% 17.49B
-0.38%+5.48%+82.20% - 15.49B
Average +0.12%+5.65%+62.28%+283.01% 24.42B
Weighted average by Cap. -0.54%+3.35%+57.38%+266.72%

Financials

2026 *2027 *
Net sales 229M 311M 263M 242M 425M 28.76B 432M 2.84B 1.11B 13.94B 1.17B 1.14B 49.14B 289M 391M 332M 305M 535M 36.23B 545M 3.57B 1.4B 17.56B 1.47B 1.44B 61.89B
Net income -9.01M -12.22M -10.35M -9.52M -16.7M -1.13B -17M -112M -43.73M -548M -45.83M -44.87M -1.93B 18.97M 25.72M 21.79M 20.05M 35.16M 2.38B 35.78M 235M 92.06M 1.15B 96.47M 94.47M 4.07B
Net Debt 26.42M 35.81M 30.34M 27.91M 48.96M 3.31B 49.82M 327M 128M 1.61B 134M 132M 5.66B -4.77M -6.47M -5.48M -5.04M -8.84M -598M -9M -59.03M -23.15M -290M -24.26M -23.75M -1.02B
Logo Oxford Biomedica plc
Oxford Biomedica PLC is a contract development and manufacturing organization (CDMO) in cell and gene therapy. It provides viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. It offers several technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the Tetravecta system), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. It has bioprocessing and manufacturing facilities across Oxfordshire, United Kingdom, Lyon and Strasbourg, France and near Boston, MA, United Sates. Its Platform segment is involved in bioprocessing and process development activities undertaken for third parties. Its Viral Vector includes LentiVector platform, inAAVate platform, and Other Viral Vectors. Its LentiVector platform technology is an advanced lentiviral vector-based gene delivery system.
Employees
977
Date Price Change Volume
26-04-17 641.00 p +3.39% 118,022
26-04-16 620.00 p -0.16% 140,203
26-04-15 621.00 p -0.64% 267,266
26-04-14 625.00 p +9.27% 322,466
26-04-13 572.00 p +1.06% 162,586
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
6.410GBP
Average target price
8.429GBP
Spread / Average Target
+31.49%

Quarterly revenue - Rate of surprise